AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions:

Listing of Claims:

- 1. (currently amended) A method of treating myelodysplastic syndromes, lymphomas and leukemias, and solid tumors comprising cells that express constitutively active mutant FLT-3 in a mammal which comprises treating the mammal in need of such treatment simultaneously, concurrently, separately or sequentially with pharmaceutically effective amounts of (a) a FLT-3 inhibitor, or a pharmaceutically acceptable salt or a prodrug thereof.
 and (b) a histone deacetylase inhibitor (HDAI), or a pharmaceutically acceptable salt or a prodrug thereof.
- 2. (original) The method according to claim 1 for treating acute myeloid leukemia (AML) .
- 3. (cancelled)
- (currently amended) The method according to claim 1, wherein the <u>FLT-3 inhibitor is a</u> staurosporine derivative is selected from the compounds of formula,

$$(R_i)_m \xrightarrow{s} (R_j)_m ($$